Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject

• US 20100092463A1
• Filed: 11/20/2009
• Published: 04/15/2010
• Est. Priority Date: 07/24/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Wood, Lowell L. JR.
• Application Number:
  US12/592,214
• Publication Number:
  US 20100092463A1
• Time in Patent Office: Days
• US Class Current: 514/1.1
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/4412 having oxo groups directly attached to the heterocyclic ring
• CPC Class Codes: A61K 31/53 having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine melarsoprol A61K31/555 ; with four nitrogen atoms A61K31/495
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61P 19/10 for osteoporosis

Abstract

A method is described for treating or preventing a bone loss disease or a bone loss disorder in a mammalian subject or reducing the incidence of a bone loss disease or a bone loss disorder or alleviating the symptoms thereof. The method includes providing to the mammalian subject at least one treatment regimen including at least one follicle-stimulating hormone modulator configured to and in an amount sufficient to reduce bioactivity or bioavailability of follicle-stimulating hormone in the mammalian subject.

Claims

1-58. -58. (canceled)

59. A method for maintaining a substantially physiological cyclic pre-menopausal level of follicle-stimulating hormone in a female subject comprising:

providing to the mammalian subject at least one treatment regimen including at least one follicle-stimulating hormone modulator configured to and in an amount sufficient to reduce bioactivity or bioavailability of follicle-stimulating hormone in the female subject, and to approximate the level of bioactive or bioavailable follicle-stimulating hormone to a target cyclic physiological pre-menopausal effective level in the female subject.

60. The method of claim 59, wherein the at least one follicle-stimulating hormone modulator includes an inhibitor of follicle-stimulating hormone bioactivity.

61. The method of claim 59, wherein the at least one follicle-stimulating hormone modulator includes a follicle-stimulating hormone receptor antagonist.

62. The method of claim 59, wherein the at least one follicle-stimulating hormone modulator includes an inhibitor of osteoclast activity.

63. The method of claim 59, wherein the at least one follicle-stimulating hormone modulator includes a small chemical molecule, polypeptide, nucleic acid, or antibody.

64. The method of claim 59, wherein the at least one treatment regimen further includes providing replacement therapy including one or more steroid hormones or metabolites or modulators thereof.

65. The method of claim 64, wherein the at least one treatment regimen is determined based on population data of physiological cyclic disease-free levels of the one or more steroid hormones in one or more mammalian subjects.

66. The method of claim 64, wherein the at least one treatment regimen including the least one replacement therapy is configured to increase levels of one or more of an estrogen or a progestogen, or metabolites or modulators thereof.

67. The method of claim 64, wherein the at least one treatment regimen includes replacement therapy with one or more of an estrogen or a progestogen.

68. The method of claim 64, wherein the at least one treatment regimen is determined based on disease-free cyclic levels of steroid hormone in the mammalian subject and on current cyclic levels of steroid hormone in the mammalian subject.

69. The method of claim 59, wherein the at least one treatment regimen is determined based on disease-free cyclic levels of follicle-stimulating hormone in the mammalian subject and on current cyclic levels of follicle-stimulating hormone in the mammalian subject.

70. The method of claim 59, wherein providing the at least one treatment regimen further includes providing a cyclic treatment regimen including at least one gonadotropin-releasing hormone modulator.

71. The method of claim 64, wherein the target cyclic physiological disease-free level includes cyclic pulsatile levels of one or more of gonadotropin, follicle-stimulating hormone, luteinizing hormone, gonadotropin-releasing hormone, or steroid hormones.

72. The method of claim 71, wherein the target cyclic physiological disease-free level of the follicle-stimulating hormone is based on population data of cyclic physiological disease-free levels of one or more of gonadotropin, follicle-stimulating hormone, luteinizing hormone, gonadotropin-releasing hormone, or steroid hormones in one or more mammalian subjects.

73. The method of claim 59, wherein the cyclic physiological disease-free level includes a cyclic physiological premenopausal level in the mammalian subject.

74. The method of claim 64, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological disease-free levels.

75. The method of claim 59, further including determining the one or more gonadotropin levels or the one or more steroid hormones levels in the subject during a treatment period.

76. The method of claim 75, wherein the treatment period includes a time period preceding treatment with the at least one follicle-stimulating hormone modulator.

77. The method of claim 75, wherein the treatment period includes a time period during treatment with the at least one follicle-stimulating hormone modulator.

78. The method of claim 77, wherein the determining of the one or more gonadotropin levels or the one or more steroid hormones levels occurs at multiple time points during the treatment period.

79. The method of claim 59, wherein the at least one treatment regimen is determined based at least in part on one or more of a time-history of gonadotropin levels or serum steroid hormone levels in the subject, on inferred peak values or minimal values of serum gonadotropin levels or serum steroid hormone levels in the subject, on age of the subject, or on categorization relative to profiles of patient populations.

80. The method of claim 59, wherein the at least one treatment regimen is determined based at least in part on Fourier analysis of the cyclic gonadotropin levels or the cyclic steroid hormone levels in the subject, or on harmonic analysis of the cyclic gonadotropin levels or the cyclic steroid hormone levels in the subject.

81. The method of claim 59, wherein the at least one treatment regimen is determined based at least in part on scaled values of the gonadotropin levels or the steroid hormone levels prior to the disease diagnosis in the subject.

82. The method of claim 81, wherein the at least one treatment regimen is determined based at least in part on the scaled value approximately equal to one.

83. The method of claim 81, wherein the at least one treatment regimen is determined based at least in part on the scaled value dependent on age of the subject.

84. The method of claim 59, wherein the at least one follicle-stimulating hormone modulator includes a gonadotropin releasing hormone antagonist, FSH inhibitor, FSH synthesis inhibitor, FSH secretion inhibitor, or FSH receptor antagonist.

85. A system, comprising:

a sensor configured to detect one or more hormones in one or more tissues of the mammalian subject; and

a controller in communication with the sensor, wherein the controller is configured to provide at least one treatment regimen including at least one follicle-stimulating hormone modulator configured to and in an amount sufficient to reduce bioactivity or bioavailability of follicle-stimulating hormone in the mammalian subject, and to approximate the level of bioactive or bioavailable follicle-stimulating hormone to a target cyclic physiological pre-disease effective level in the mammalian subject.

86. The system of claim 85, wherein the one or more hormones includes follicle-stimulating hormone, luteinizing hormone, or steroid hormone.

87. The system of claim 86, wherein the steroid hormone includes estrogen, progestogen, or testosterone.

88. The system of claim 85, wherein the at least one follicle-stimulating hormone modulator includes an inhibitor of follicle-stimulating hormone bioactivity.

89. The system of claim 85, wherein the at least one follicle-stimulating hormone modulator includes a follicle-stimulating hormone receptor antagonist.

90. The system of claim 85, wherein the at least one follicle-stimulating hormone modulator includes an inhibitor of osteoclast activity.

91. The system of claim 85, wherein the at least one follicle-stimulating hormone modulator includes a small chemical molecule, polypeptide, nucleic acid, or antibody.

92. The system of claim 85, wherein the at least one treatment regimen further includes providing replacement therapy including one or more steroid hormones or metabolites or modulators thereof.

93. The system of claim 92, wherein the at least one treatment regimen is determined based on population data of physiological cyclic pre-disease levels of the one or more steroid hormones in one or more mammalian subjects.

94. The system of claim 92, wherein the at least one treatment regimen including the least one replacement therapy is configured to increase levels of one or more of an estrogen or a progestogen, or metabolites or modulators thereof.

95. The system of claim 92, wherein the at least one treatment regimen includes replacement therapy with one or more of an estrogen or a progestogen.

96. The system of claim 92, wherein the at least one treatment regimen is determined based on pre-disease cyclic levels of steroid hormone in the mammalian subject and on current cyclic levels of steroid hormone in the mammalian subject.

97. The system of claim 85, wherein the at least one treatment regimen is determined based on pre-disease cyclic levels of follicle-stimulating hormone in the mammalian subject and on current cyclic levels of follicle-stimulating hormone in the mammalian subject.

98. The system of claim 85, wherein providing the at least one treatment regimen further includes providing a cyclic treatment regimen including one or more of at least one gonadotropin, or at least one gonadotropin-releasing hormone modulator.

99. The system of claim 92, wherein the target cyclic physiological pre-disease level includes cyclic pulsatile levels of one or more of gonadotropin, follicle-stimulating hormone, luteinizing hormone, gonadotropin-releasing hormone, or steroid hormones.

100. The system of claim 99, wherein the target cyclic physiological pre-disease level of the follicle-stimulating hormone is based on population data of cyclic physiological pre-disease levels of one or more of gonadotropin, follicle-stimulating hormone, luteinizing, hormone, gonadotropin-releasing hormone, or steroid hormones in one or more mammalian subjects.

101. The system of claim 85, wherein the at least one follicle-stimulating hormone modulator includes a gonadotropin releasing hormone antagonist, FSH inhibitor, FSH synthesis inhibitor. FSH secretion inhibitor, or FSH receptor antagonist.

102-104. -104. (canceled)